<DOC>
	<DOCNO>NCT00735787</DOCNO>
	<brief_summary>Evaluate efficacy safety 16-week course Humira ( adalimumab ) compare placebo adult chronic plaque psoriasis hand and/or foot sustainability response 12 additional week .</brief_summary>
	<brief_title>Controlled Study Humira Subjects With Chronic Plaque Psoriasis Hands and/or Feet</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult Diagnosis chronic plaque psoriasis Hands Feet least 6 month , PGA &gt; /=3 candidate systemic therapy ; Patients good general health Able selfadminister injection Negative chest xray ( CXR ) purify protein derivative ( PPD ) test , unless willing start antituberculosis ( TB ) prophylaxis Previous treatment HUMIRA® Required mediation stability washout : systemic corticosteroid ( 28 day ) , investigational agent , systemic therapy psoriasis , ultraviolet B ( UVB ) , psoralen UVA ( PUVA ) Other active skin disease skin infection Diagnosis palmoplantar pustulosis ; erythrodermic psoriasis , pustular psoriasis , medicationinduced exacerbate psoriasis new onset guttate psoriasis Evidence dysplasia history malignancy ( Other successfully treat nonmetastatic cutaneous squamous cell , basal cell carcinoma localize carcinoma situ cervix ) ; History listeriosis , histoplasmosis , chronic active Hepatitis B infection , human immunodeficiency virus ( HIV ) infection , immunodeficiency syndrome , chronic recur infection active tuberculosis ( TB ) ; History moderate severe congestive heart failure , Recent cerebrovascular accident condition , opinion investigator , would put subject risk ; History central nervous system ( CNS ) demyelinate disease neurologic symptom suggestive CNS demyelinate disease ; History clinically significant drug alcohol abuse last 12 month ; Infection ( ) require treatment intravenous ( IV ) antibiotic , IV antiviral , IV antifungal within 30 day prior Baseline oral antibiotic , oral antiviral , oral antifungal within 14 day prior Baseline ; Known hypersensitivity excipients HUMIRA® state label ; Female subject pregnant breastfeed consider become pregnant study . Prior exposure Tysabri® ( natalizumab )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>